^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Published date:
04/28/2020
Excerpt:
...primary endpoints were PFS and overall survival (OS) among patients with PD-L1+ tumors. PFS was significantly longer in the avelumab plus axitinib arm than in the sunitinib arm (PD-L1+ population: hazard ratio [HR] 0.62 [95% CI, 0.490-0.777]…
DOI:
10.1016/j.annonc.2020.04.010
Trial ID:
Source:
Title:
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Excerpt:
Among the patients with PD-L1–positive tumors, the objective response rate was 55.2% with avelumab plus axitinib and 25.5% with sunitinib...
DOI:
10.1056/NEJMoa1816047
Trial ID:
Source:
Title:
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study). Studio di fase II sull’uso in prima linea di avelumab in combinazione con axitinib intermittente in pazienti con carcinoma renale metastatico (studio Tide-A)
Excerpt:
...• Progression free survival in the overall population• Overall response rate in the overall population• Disease control rate in the overall population• Safety of the combination and of the avelumab alone after the combination.• To evaluate the Health-Related Quality Of Life (HRQOL) according to FKIS-19 questionnaire and Health status/utility (EQ-5D-5L) test.• To test the predictive role of the immunohistochemistry expression of PBRM1, PD-L1, CD31 and immune infiltration CD8+.• To evaluate the changes citokines evaluated at baseline, after 8 weeks of therapy and at tumor progression. ...
Trial ID:
